SHRX — Sharp Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$63.16m
- CA$63.61m
Annual cashflow statement for Sharp Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Net Income/Starting Line | -0.011 | -0.021 | -0.137 | -3.26 | -6.17 |
| Depreciation | |||||
| Non-Cash Items | — | — | 0.024 | -0.515 | 0.946 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.011 | 0.025 | -0.016 | 0.06 | 0.299 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0 | 0.004 | -0.129 | -3.62 | -4.83 |
| Capital Expenditures | — | — | — | -0.014 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0.005 | 0 |
| Sale of Business | |||||
| Cash from Investing Activities | — | — | — | -0.009 | 0 |
| Financing Cash Flow Items | 0.063 | -0.012 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.063 | 0.05 | 0.312 | 6.73 | 2.32 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.063 | 0.054 | 0.182 | 3.11 | -2.53 |